Member Info for Pingu777

I think there might be a nominal upfront payment for CDX JHFH. We’ve self funded Car T as you say so a new JV might appear there within a few months. And then HuPech were with Orgenesis so that is that. We are due an update on HuPech and it should be just about ready for phase 1 trials.

Percentages of all of those treatments and then... we’re back to the mice!!!! Immediate income stream stated already. Just how good are they though?

Notice little mention of COVID you COVID chasers?

Not a bad shout but not big enough imo.

GlobalCo more suited for me. But, I think that’s a fair while off yet.

Mouse update please Vlad. They must be getting restless now with all this “hush hush”.

Give us a squeak...

A bidding would be ideal as it would ensure we didn’t Get scooped up on the cheap.

£1b Vlad (if you’re reading :-) and I’ll think about it.

JHFH, what sort of upfront advances payment might you see us getting for our drugs once the JV is up and running for phase one trials?

I’m very keen to see how testing on our mice impacts the human phases and hopefully reduces timescales dramatically.

Who would win in a fight between a monkey and a hundred mice? Sometimes you’ve got to ask yourself these questions.

I feel a lot like HEMO are lining their ducks up for a take over. And I hope we don’t get duped price-wise if we do.

All three drugs reaching human phase one trial within a couple of months- imo.

Mice the best they can be.

I think our business is in the shop window and Vlad will be having relevant discussions. So a slight tweak on the question. How much does Vlad want for everything?

Let’s be clear. As far I am concerned Nobody else has any tech anywhere near ours.

Having solved the graft versus host problem the mice allow detailed testing to continue and remain affective long into the life of the mouse.

No one else has this capability! They run their tests but their results are limited thus requiring significant continued work into human phased trials. Thus taking so much longer to perfect and sometimes find hidden problems.

Problems have nowhere to hide on HEMO mice. If your drug passes the HEMO mouse test then it’s got a rubber stamp no one else anywhere other than HEMO is able to give.

-HEMO CAR T THERAPY
-HuPech stem call treatment
-CDX neutralising antibodies
-ApbHC humanised mice
- Covid research

Janssen/ Lupus disease modelling
Orgenesis - HuPech development and delivery point of care
- biodefense platform
GlobalCo - CDX to phase 1 human trials shortly
- 8 months is ApbHC development work

So what’s it all worth?

Absolutely JHFH, these are the sort of calculations guesstimations that give you an indication of the companies potential.

If we’ve developed further improvements the our already ground-breaking mice how do you value that? Well, speculating at their impact let’s say that they Reduce the pre-clinical testing period by half. Let’s suggest that the pre-clinical testing with our mice becomes so ruthlessly deep and affective that is significantly reduces the chances of failure during human trials. Let’s say that as a result of our incredible mice testing human trials half in timescales as less work is needed to tweak it as they’ve got it so right in pre-clinicals.

How much is that worth to a single Pharma who spends tens and sometimes hundreds of mIllions throughout the drug development process?

How much is that worth to a number of pharmas? Many big pharmas? Most big pharmas?

Why wouldn’t they all want the mice?

So, I want an update on our mice developments with GlobalCo. What additional drugs and treatments are we able to test and model on the even newer and even more improved super mice?

So let me get this straight. You invested 2yrs ago when HEMO was literally at the outset of designing a product portfolio. Before any positive testing results. Before the mice were developed. At 2p a share.

But now, after HEMO has reached the cusp of quite frankly a transformational period for the company, products lined up knocking on the door of phase 1 testing, with exemplary results throughout the pre-clinical testing, its “too risky”?

Someone needs to stop telling porkies. Or needs to give up the game!

And sorry, if GlobalCo says no? How much confirmation do you need! Read that last RNS again! Two years in and then they decide its not for them?!?

Are you being serious?

I know lots of pharmas have humanised mice. But I don’t think you understand how good ours are.

One of the main updates I’d like to hear is the improvements made to the mice as part of the GlobalCo deal agreed in October. I expected an update to come with the GlobalCo announcement and the CDX work. I hope something is released soon.

Delano. Do you understand the phenomenal powers of the humanised mice? One key feature is that they allow significantly more testing and validation than any other animal testing out there. These pre-clinical tests provide and a significantly enhanced chance of human trials succeeding - proving the treatment is successful in said mice.

Why would you wait until an official announcement to invest on triple the SP when the details of potential success are right in front of you?

CDX, proven to work on ALL and in particular AML, which has no other treatment currently apart from chemo and radiotherapy. What would you say that is worth?

And our £29m MCAP is too high? On a single Successful treatment alone that gets blown out of the water.

What about the HuPECH stem cell therapy being Developed and delivered via ORGS through their point of care hospital partnerships?

What about our HEMO Car T Cell therapy? A version currently sold by Novartis at $375k a pop.

What about our mice? How did Eli Lilly swoop from nowhere to speed through pre-clinicals to reach human testing of neutralising antibodies So fast?

One central theme (well 2)... neutralising anti-bodies.... and ApbHC.

DYOR.

HEMO a gamble? If your investment timescale is a week maybe. If you’re investing for 12-18m then I have not found any other share with as high a Multi-bag potential with such little downside risk. DYOR.

Not directed at you Grant! :-)

We're expecting them to have created and developed a treatment for those who can't be bothered to read RNSs.

And GlobalCo. Entered an agreement in October to work on them together. I think they’ll certainly one more going forward.

There is no doubting the credentials of the HEMO teams and it’s potential to deliver on all projects upon which it is working. Their tech is astonishing as has been communicated to everyone. This company will be transformed once news starts to flow.

Simply read the year end update from start to finish. It is all there.

Lols.